434
Views
60
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Presurgical Trial of Metformin in Overweight and Obese Patients with Newly Diagnosed Breast Cancer

, , , , , , , , , , & show all
Pages 150-157 | Received 22 Oct 2013, Accepted 28 Jan 2014, Published online: 07 Mar 2014
 

Abstract

Introduction: We conducted a presurgical trial to assess the tissue-related effects of metformin in overweight/obese breast cancer (BC) patients. Methods: Metformin 1,500 mg daily was administered to 35 nondiabetics with stage 0–III BC, body mass index (BMI) ≥ 25 kg/m2. The primary endpoint was tumor proliferation change (i.e., ki-67). Tumor proliferation change was compared to untreated historical controls, matched by age, BMI, and stage. Results: There was no reduction in ln(ki-67) after metformin (p = .98) or compared to controls (p = .47). There was a significant reduction in BMI, cholesterol, and leptin. Conclusion: Despite no proliferation changes, we observed reductions in other relevant biomarkers.

Table S1 Changes in Absolute Tumor Proliferation (ki-67) in Evaluable Metformin-Treated Patients and Matched Historical Controls

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.